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Objective: This study aimed to evaluate the efficiency of treatment of infectious endocarditis (IE) via Self-
administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT) supported by a shortening hospital 
admission program in a hospitalization-at-home unit (HAH), including a short review of the literature. 
Methods: Ambispective cohort study of 57 episodes of IE in 54 patients treated in an HAH unit between 1988 
and 2014 who receive S-OPAT after prior intra-hospital clinical stabilization. Characteristics of each episode of 
IE, safety and efficiency of the care model, were analyzed. 
Results: Forty-three (76%) patients were males with a median age of 61 years (SD=16.5). A total of 37 (65%) 
episodes affected the native valve (42% the aortic valve). In 75%, a micro-organism was isolated, of which 88% 
were Gram-positive bacteria. No deaths occurred during HAH program, clinical complications appeared in 30% 
of episodes, only 6 patients were re-admitted to hospital although no patient died. In the 12 months’ follow-up 3 
cases had a recurrence. The average cost of a day stay in HAH was €174 while in traditional cardiology 
hospitalization was €1100. The total average cost of treatment of each episode of IE managed entirely in hospital 
was calculated as €54,723. Application of the S-OPAT model based on HAH meant a cost reduction of 32.72%. 
Conclusions: In suitably selected patients, treatment of IE based on S-OPAT supported by a shortening hospital 
admission care program by means of referral to a HAH unit is a safe and efficient care model which entails a 
significant cost saving for the public healthcare system. 


















































Infectious endocarditis (IE) is one of the most serious infectious diseases because of its acute and unpredictable 
clinical course [1]. Despite the steps forward in diagnosis and treatment [2], its mortality continues to be very 
high (18% inpatient and 40% at one year from follow-up) [3, 4]. Its treatment consumes a large amount of 
financial resources because of prolonged hospital stay (arising from long term recommendations for parenteral 
antimicrobial treatment). However, there are hardly any works that evaluate the overall costs of its hospital 
treatment.  
Efficiency in the healthcare setting is estimated by means of financial evaluation of costs entailed by 
comprehensive management of the disease. Cost minimization analysis enables selecting the procedure which, 
with the same effect, has a lower cost [5]. Therefore, alternative care models to traditional hospitalization that 
reduce or avoid hospital admission without detriment to a benefit on health should markedly increase efficiency 
during treatment of hospital processes. 
Outpatient Parenteral Antimicrobial Therapy (OPAT), is an alternative care model to traditional hospitalization 
that has been demonstrated to be effective and safe in many infectious processes [6,7]. Most OPAT programs [8] 
mainly follow two models. First, infusion in the patient's home with active intervention of nursing personnel 
called “Healthcare Professional Outpatient Parenteral Antimicrobial Therapy (H-OPAT); and, second, “Self-
administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT)”, that is, a model in which the healthcare 
personnel initially train the patient and/or their caregivers to administer antimicrobials so that healthcare 
personnel physical presence in the home during infusion is subsequently not necessary. Recently, those of the 
variant S-OPAT [9] although more limited, are revealing similar efficacy and safety results. In both healthcare 
processes, the clinician is not too involved in daily follow-up of patients. This is generally limited to monitoring 
clinical course in the outpatient clinic over a variable period. 
In Spain, healthcare expenditure is very high and it is foreseen to increase in the future because of ageing of the 
population. Sustainability of its healthcare system which is priority in a period of financial crisis such as the one 
currently will only be possible if we attain maximum efficiency in patient care [10].  Against this backdrop, in 
our country we have a highly developed system of 150 hospital-at-home units (HAH), in which care devices are 
managed by internal medicine specialists that provide the patient in their own home diagnosis, care and hospital-
like treatments for a limited period just as if they had remained admitted in an acute hospital unit[11].Most 
HAHs have a wide list of services for the patient including intravenous antibiotic treatment (OPAT) which over 
recent years has received considerable attention. Other clinical processes addressed by HAHs include pulmonary 
embolism, acute kidney injury, post-surgery processes as well as decompensation in chronic diseases including 














































regimens according to origin of the patients. In the first, the “admissions avoidance scheme”, patients come from 
emergency services, their homes, retirement homes or outpatient clinics and avoid hospital admission. In the 
second, patients come from hospital wards and seek to shorten usual hospital admission; this is called “early 
discharge scheme” (when patients remain less than 7 days in hospital) or “shortened hospital admission scheme” 
(when the patient is admitted for more than 7 days). 
The main difference between stand-alone OPAT and HAH is that, in the latter, there is very close clinical 
follow-up by healthcare professionals. As such, the patient’s safety is increased even in complex clinical 
processes [14]. 
In the specific case of IE published works on OPAT were anecdotal until a few years ago, due mainly to the 
reticence to incorporate this complex global process into the portfolio of services for this care modality. 
However, in the last few years there has been a notable increase in the scientific evidence in this field which 
coincides with the reiterated support regarding American and European cardiology societies [15-18].  
However, there are barely any papers published regarding costs arising from treatment of IE both in hospital and 
for the OPAT care model. Another gap is that S-OPAT in the context of HAH has not been well-described, and 
most HAH centers do not utilize S-OPAT. The main aim of this study was to determine the efficiency of 
treatment of IE using S-OPAT with HAH. The former allows reduced nursing effort by training self- or 
caregiver administration of antimicrobials, while the latter gives the support of a shortening hospital admission 
















































Material and Methods 
Setting 
An ambispective cohort study of patients with IE, diagnosed according to modified Duke criteria [19], and 
admitted to the HAH unit in a third level University Hospital in Spain was performed from 1998 to 2014.  
The methodology to identify IE episodes and essential characteristics were collected in a database devised for 
the study. The HAH protocol for IE was applied, in addition to evaluation of the efficacy of the HAH program 
for S-OPAT having previously been reported [20]. 
IE episodes were diagnosed in hospitalized patients, initially treated in hospital until stabilized, and then 
transferred to the care of the multidisciplinary HAH team. Following stabilization, consensus decisions were 
taken regarding the optimum S-OPAT schedules to be conducted in the HAH therapeutic plan, which would 
include not only IE but also any minor complications that may arise. General criteria for S-OPAT treatment of IE 
within the HAH program are summarized in Table 1. 
The efficiency of S-OPAT was first estimated by calculating the cost per day of stay in the HAH by means of the 
sum of direct costs (personnel costs, pharmacy consumption, healthcare material, maintenance, amortization of 
equipment, etc.) and costs charged for other hospital services and structures. We need to point out certain details 
to understand the cost calculation made. The HAH unit has a care capacity of 56 patients/day and has a physical 
infrastructure located in hospital. The staff is made up of seven doctors, 17 nurses, seven clinical assistants and 
two administrative assistants. There are 16 automobiles financed by means of renting to undertake their care 
work. The healthcare and non-healthcare material together with the pharmacy are supplied by the hospital. Costs 
are calculated by means of evaluation of direct cost (staff, pharmacy consumption, healthcare material, 
maintenance, amortization of equipment, etc.) for the unit during 2014; to which we must add the costs charged 
for other hospital services and structures.  
And second, calculating the cost of a day stay in a traditional hospital by means of financial analysis of the 37 
patients with IE (25 with entire intrahospital care and 12 with initially intrahospital care and subsequently by 
means of HAH) who were treated in our hospital and survived during the final years of the study (2013-2014) 
with the purpose that the financial data obtained are as reliable as possible. Of the 37 patients analyzed 
individually, they were included in two different groups; an initial control group of 25 patients that received 
antibiotic treatment entirely in the hospital; the second case group comprised of the 12 patients who initially 
received intrahospital treatment followed by treatment in HAH. For each patient, the process and complications 
presented during the IE episode were evaluated coding for the diagnosis-related group (DRG) generated at 
discharge. The costs assigned to each DRG were calculated by the hospital’s analytical accounting unit using the 














































of average cost of a patient who was treated entirely in hospital compared to the patient who received combined 
treatment, was performed. 
Data analysis 
Data were introduced into a database created with the program Microsoft Excel and variables were analyzed by 
means of the statistical packages SPSS version 11.5 (SPSS Inc. Headquarters, Wacker Drive, Chicago, Illinois, 
USA).A descriptive analysis was performed expressing quantitative variables in the form of mean ± standard 
deviation (SD) and qualitative variables in the form of percentage and proportions. 
Ethical Statement 
This study was approved with code 2008.4 by the Ethics Committee of the Autonomous Community of 
Cantabria, Spain. There was compliance with the ethics principles set out in the Declaration of Helsinki and 


















































A total of 57 episodes of EI in 54 patients were included in the study;23 episodes were collected from the 
retrospective period (1998-2007) and 34 were collated prospectively (2008-2014). This is equivalent to 9.1 % of 
the total of 624 IE episodes treated by the infectious disease unit of our hospital over that period.  
Patients baseline characteristics (basic epidemiological variables, associated comorbidities and history of heart 
valve disease) and the specific features of the IE episodes are summarized in Table 2. 
The S-OPAT program showed high efficacy as shown by the results summarized in Table 3. No patient died at 
home. Clinical complications appeared in approximately 30% of episodes. Six patients had to return to hospital 
none of whom died in hospital and two of them returned to the HAH unit to complete their S-OPAT. During the 
one year follow upto the initial episode, two patients presented a relapse of IE: one of them on two occasions, 
both requiring surgery because intravenous antibiotic treatment failed. In the other patient, the relapse responded 
favorably to specific antibiotic treatment and did not present subsequent complications.The results of our current 
series of 57 episodes of IE and those of other series published that applied different OPAT regimens are 
summarized in Table 4. 
Costs are calculated by means of evaluation of direct cost (staff, pharmacy consumption, healthcare material, 
maintenance, amortization of equipment, etc.) for the unit during 2014; to which we must add the costs charged 
for other hospital services and structures (see Table 5). The cost of one day stay in HAH is calculated 
considering the care data for the HAH unit during 2014 that treated 1,567 admissions which generated a total of 
20,480 stays. The overall cost of the unit was €3,569,519, whereby the average cost of the stay turned out to be 
€174.29. During the estimate of traditional hospitalization 15 different DRGs were used to evaluate cost arising 
from treating 37 patients chosen for this purpose. Therefore, weighting for the stays attributed to each DRG 
generated by the processes involved (1,562 stays) and quantifying the price/stay for each one of them, an average 
cost of €1166.80 per day stay was determined. 
For the comparative analysis of costs between treatment of IE according to the traditional regimen (only 
hospital) and combined treatment model (initially in hospital, subsequently the HAH unit), we need to ascertain 
the average stay of both groups of patients. In the case of the control group 25 patients received comprehensive 
treatment on a hospital ward and their average stay was 49 days. Average stay was also 49 days for the case 
group of 12 patients that received combined treatment (30 days in hospital and 19 days in the HAH unit). With 
these data, once the cost/stay of the two models and the number of stays to apply in each one of them are 
identified, the final results are those shown in Table 6. That is, the average total cost of treating an episode of IE 














































was 36,815.58 euros. From this, we deduce that the combined treatment model saves 17,907.64 euros per 

















































This study shows the efficiency of treatment of patients with IE by means of S-OPAT in comparison with a 
traditional hospitalization model.  
The OPAT model has undergone modifications during our study’s broad period in accordance with the onset of 
new antimicrobials and scientific evidence that led to modifications in traditional antimicrobial 
recommendations for different infectious processes [21] 
Treatment at home by means of various care modalities of infections with traditional criteria for hospitalization 
is now consolidated with excellent results regarding efficacy, reducing hospital stays, reducing costs of the 
process and proving to be satisfactory for the patient [22,23]. In the case of IE, because this is a complex 
infectious process, it was incorporated into treatment under this care model at a late stage, whereby there is little 
prior experience in this regard [20, 24, 25]. Nonetheless, the repeated support shown both by the American Heart 
Association (AHA) [17,18] and the European Society of Cardiology (ESC) [15,16] in the last few years, 
including OPAT in its clinical guidelines as a care modality for IE in selected patients, has led to an increased 
publication of works, thereby guaranteeing this care option [26-31].  
To date, in most published series on OPAT for IE the H-OPAT model predominated; S-OPAT was clearly the 
minority option. In our previous work [20] we observe that, because the characteristics of patients and episodes 
of IE were very similar to previous series, the efficacy of the S-OPAT program was excellent because no patient 
died and the rate of unexpected returns to hospital and relapse was similar to that of other recently published 
series[28,31]. Moreover, the paper we present here extends the previously published seriesby9 episodes and is 
the largest series published in the literature of IE patients who underwent S-OPAT. The results found not only 
consolidate those obtained previously but they improve them. Our work verifies that the S-OPAT care model is 
safe and effective to treat IE. Therefore, our care alternative obtains similar healthcare results to the traditional 
hospitalization model. Furthermore, our data show that between the two care procedures the combined treatment 
strategy is clearly more efficient than the classical strategy and provides an estimated cost saving of almost 33%. 
In a recent review of the OPAT model it was notified that this represents a significant cost reduction in 
comparison to the traditional hospitalization model but there are still insufficient studies to generalize this 
statement [32]. In the last few years, papers have been published that try to confirm that this care model, in 
addition to being effective and safe, is also efficient. Most works are based on the Anglo-Saxon variant of H-
OPAT and the methodology used for the financial analysis consists of determining the potential saving arising 
from less day stay cost attributed to the OPAT in comparison to traditional hospitalization [22,33-36].A British 














































infectious diseases hospital ward [22]. An American group [33] analyzed 398 clinical processes, where OPAT 
meant a saving for the hospital of $4 million. Another Canadian study estimated a day cost for OPAT of 14% 
compared to traditional hospitalization [34].   
Our work provides data on the day stay cost of our HAH but also because it comprehensively lists both direct 
and indirect costs attributed to our model, a model which has not been comprehensively studied and for which 
there is very little literature. In this regard, there are no financial evaluation works comparing the different 
variants of our OPAT. However, the few studies published [35, 36], appear to support the fact that the S-OPAT 
modality reduces costs more than the H-OPAT model. An American group [35] notified that the cost of the S-
OPAT represented 10% of the cost of hospitalization. Subedi S, et al [36] estimated in Australia that the cost of 
the S-OPAT was $150 per day stay whilst in hospital it was $500-800. According to all the studies, the reduced 
price of the process in comparison to H-OPAT would mainly be due to the cost reduction arising from nursing 
staff given that because it is the patient themself and their caregivers who administer S-OPAT, this leads to a 
drastic reduction in visits by this staff. 
We also estimated a day stay cost of the HAH of €174.29, very similar to that published in most articles on S-
OPAT. However, because the HAH is based on the complexity of our S-OPAT model, this is much higher than 
that of any other variant of the OPAT model, whereby we can state that in this context, our model increases the 
efficiency of the S-OPAT even further if possible. 
In the scope of IE, the little information available on the costs of its treatment in a traditional hospitalization unit 
is surprising. IE is probably one of the most expensive infectious diseases within the portfolio of services offered 
by a tertiary level hospital. A French group [37] recently published the financial costs of treating IE, resulting in 
an average cost of €17,735 in 2009, which increased by 34% during the three years the study lasted. In our study, 
we estimated an average cost of treating an episode of IE at €54,733.22, figures well above that published by the 
French group although we believe our figure is more accurate. Possibly their data are underestimated because the 
baseline analysis in the DRG assigned exclusively to IE and obviously, this method is incomplete because it does 
not evaluate each patient individually and we lose data for those complications that occur during the entire 
clinical course of the disease. 
Another French OPAT group [38] published a retrospective study of 39 episodes of IE treated in the hospital, of 
which 18 were selected for H-OPAT. The study revealed a day stay price of €140 (not accounting for 
pharmaceutical costs) H-OPAT; the price of hospital day stay in an infectious disease unit was €1140, meaning a 
final saving of €14,850 per patient. In our series, not only did we obtain higher efficiency given that we saved 














































of 17.5% whilst in our case this was 10.5%. These data are of great interest because it confirms that our S-OPAT 
model is not only more efficient but also safer than the H-OPAT model. The OPAT model in Spain [12, 13] is 
applied thanks to HAH units, which provide comprehensive management of the infectious disease at the 
patient’s home, because professionals travel to the home to perform clinical monitoring during the disease. In the 
Anglo-Saxon model follow-up is performed by the nurse whilst the professional remains at the hospital where 
the patient comes to be periodically re-evaluated [14].Regular visits at home by the professional guarantee 
similar clinical outcome to that offered in hospital, thereby increasing the patient’s safety by being able to detect 
the onset of complications early and commence their treatment earlier, thereby avoiding readmission to hospital.  
Our results have a high degree of internal validity in that the record of data from variables chosen for the study 
was comprehensive and there was no loss of information. Further, the health-care scheme of the S-OPAT was 
supported by the HAH team which has had many years of experience in this area. Since its origins in 1984, the 
administration of intravenous drugs has formed part of the list of services for patients at home. However, this 
study has some limitations. First, the specific characteristics of our HAH Unit are dependent on a (University) 
hospital providing advanced care in close collaboration with medical and surgical specialists involved in the 
management of IE. It can respond rapidly to any clinical incident in the patient's home. All these characteristics 
make it difficult to extrapolate our conclusions on the safety and efficacy of the health-care model to other 
health-care contexts. Second, the low number of patients included in our study sample would tend to limit the 
reproducibility of our scheme in other contexts. 
Conclusion 
In summary, IE is a very expensive clinical process; an average of €54,723 per episode is estimated and the 
application of two combined care models (initially traditional hospitalization and, subsequently, hospitalization-
at-home) clearly increases its efficiency because this means a cost saving of 32.72% without undermining safety 
and effectiveness.  
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Table 1. Inclusion criteria for an episode of IE in the HAH shortening hospital admission program of the HUMV 
General: 
Voluntary participation by the patient and carer(s) after being informed about the 
functioning of the HAH 
Requirement for a 24 h/day carer in the home of the patient 
HAH operating within the catchment area of 15 km from the hospital 
Specific: 
Commitment on the part of the patients and carer(s) to the S-OPAT scheme  
Clinical stability (no fever, hemodynamic stability, no cardiac insufficiency, no focal neurological 
disease 
Laboratory criteria (normal leucocyte distribution, decreasing C-reactive protein levels and stable renal 
function 
Absence of atrial-ventricle blockage confirmed using an electrocardiogram 
Echocardiographic assessment to confirm decreased size of vegetation and/or absence of para-valvular 
complications following at least 1 week with suitable antibiotics 
HAH: hospitalization-at-home; HUMV: Hospital Universitario Marqués de Valdecilla; IE: Infective 












































































Table 2. Basal characteristics and specific features of the IE episodes                                                              
Basal characteristics  
Age (mean,SD) 61(16.5) 
Males (n, %) 43(75.9) 
Existence of comorbidity (n, %) 47(83.3) 
Charlson index (mean, SD)  2.6(2.4) 
Hypertension (n, %) 26(45.6) 
Diabetes (n, %) 11(19.2) 
Non-valvular chronic heart failure (n, %)   8(14.5) 
Chronic Obstructive Pulmonary Disease (n, %)   6(10.4) 
Chronic renal disease (n, %) 13(22.9) 
Neoplasia (n, %)   9(16.6) 
Chronic liver disease (n, %)     5(8.7) 
Previous valve disease (n, %) 32(56.1) 
Prior valve disease operated surgically (n, %) 20(33.3) 
Previous infectious endocarditis (n, %)    4(7.4) 
Specific features of the IE 
Type of valve affected (n, %) 
Native  37(64.9) 
Prosthesis 20(35.1) 
Location of the valve affected (n, %) 
Mitral  24(42.1) 
Aortic  24(42.1) 
Mitro-aortic  5(8.7) 
Pulmonary  2(3.5) 
Tricuspid  2(3.5) 
Site of acquisition (n, %) 
Community  39(64.9) 
Nosocomial/Healthcare Relations. 18(35.1) 
Need for heart surgery (n, %)                                                                        20(35.1) 
Documented principal micro-organism (n, %)  
Staphylococcus aureus  10(23.2) 
CNS2  10(23.2) 
 Viridans group Streptococci 9(20.9) 
Streptococcus bovis 3(6.9) 
Enterococci 3(6.9) 
Other* 10(23.2) 
Antibiotic most commonly used (n, %) ** 
Ceftriaxone  17(29.8) 
Vancomycin  10(17.5) 
Ampicillin  7(12.5) 
Daptomycin  7(12.5) 
Penicillin G                                                                                                                                          5(8.7) 
Linezolid                                                                                                                                              5(8.7) 
Teicoplanin      3(5.2) 
Cloxacillin     3(5.2) 
Duration of treatment (weeks, SD)  
 Intrahospital                                                                                                                                      2.1(0.9) 
 HAH            3.1(0.9) 
CNS: Coagulase negative staphylococci; COPD: Chronic Obstructive Pulmonary Disease; HAH: hospitalization-
at-home IE: infectious endocarditis; SD: standard deviation 
*Other documented micro-organisms: Streptococci pneumonia (1, 2,3%), Abiotrophia defectivus (1, 2.3%), 
Aggregatibacter aphrophilus (1, 2.3%), Escherichia coli (1, 2.3%), Haemophilus parainfluenzae (1, 2.3%), 
Listeria monocytogenes (1, 2.3%), Providenza rettgeri (1, 2.3%), Salmonella typhimurium (1, 2.3%). 
** Other Antibiotics used: cefazolin, ertapenem, gentamycin, meropenem Comment [Ref2-1]: Do generics 
















































Table 3. Efficacy of the HAH program for S-OPAT during IE 
 
Characteristics                                                                                                                            n(%) 
  
     Mortality (n, %) 0 
  
     Major complications requiring unexpected return (n, %) 6 (10.5) 
         Anaphylaxis secondary to allopurinol  
         Moderate hypopotassaemia  
         Hepatorrenal syndrome  
         Multifactorial renal failure   
         AV blockade requiring pacemaker  
         Respiratory sepsis requiring ITU  
  
     Complications resolved at home (n, %) 11(19.2) 
         4 episodes of congestive heart failure  
         3 episodes of catheter-related infection  
         4 episodes of acute drug reactions  
                -Vancomycin red man syndrome  
                -Vancomycin drug fever  
                -Abnormal liver function tests to rifampicin  
                -Acute kidney injury because of aminoglucosides  
  
        Relapse (n, %) 3(5.2) 
  
HAH: hospitalization-at-home; IE: Infective endocarditis; ITU: intensive therapy unit; S-OPAT: self-























































Table 4. Outcome of IE in different OPAT series 






























IE Episodes 57 40 43 100 73 36 80 
Outcome         
  Mortality (%) 0 0 0 0 4 2.7 1.2 
  Unexpected 
returns (%) 
10.5 7.5 23 10 16 11 26 
  Relapse (%) 5.2   5  2.7 8.7 
H-OPAT: healthcare outpatient parenteral antimicrobial therapy; IE: Infective endocarditis; OPAT: Outpatient 
































































Professionals                               713,154 
Nursing                                      1,030,173 
Auxiliary assistants                       223,691 
Administrative assistants               57,526 







Pharmaceutical products             540,596 
Other Healthcare Material              90,462 
Blood bank                                   16,100 
Oxygen therapy                            108,849 
Renting vehicles                            67,805 
Fuel vehicles                               18,237 
Amortizations                                 6142 
 TOTAL                                       848,191 
  
Costs charged from other services 696,784 
 Total Costs                            3,569,519 
 
Day stay cost 174.29 
 
































































IE episode (Euros) 
 
Total cost (Euros)  
     
Hospital alone 49 1116.80 54,723.22 54,723.22  




30 plus 19 days  174.29 33,504.02 plus 3,311.57 36,815.58
HAH: hospitalization-at-home; IE: Infective endocarditis 
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